Salvo Health Secures Exclusive Tech to Reshape Chronic GI Care

MILWAUKEE, WI – March 06, 2026 – In a significant move to redefine the management of chronic gastrointestinal conditions, virtual care platform Salvo Health is deepening its strategic partnership with medical device innovator Lohman Technologies. The expanded collaboration will see the large-scale deployment of Lohman’s FDA-cleared HomECG+ monitoring device across Salvo’s network, providing what the companies describe as a new, more integrated approach to treating GI and metabolic disorders.

Building on a successful 2024 pilot, the alliance will extend the use of the home monitoring technology to Salvo’s partner GI clinics in six new states: Ohio, Virginia, Maryland, Colorado, Massachusetts, and Washington. This expansion adds to existing deployments in Georgia, Florida, Michigan, and New York, signaling a major push to integrate advanced remote patient monitoring into mainstream gastroenterology. The partnership aims to tackle a widespread healthcare challenge, as over 60 million Americans suffer from chronic GI issues while being served by fewer than 20,000 specialists.

A Strategic Edge in a Crowded Market

At the heart of the deal is a key competitive differentiator for Salvo Health. According to Lohman Technologies President Jason Dvorak, the agreement grants Salvo exclusive access to the HomECG+ device for use in the GI wraparound care sector. "Salvo Health now holds a clear competitive advantage," Dvorak stated, highlighting the device's unique position in the market.

This exclusivity could provide a substantial boost to Salvo Health in the rapidly growing digital health industry. The company has already demonstrated impressive momentum, reporting an 800% year-over-year increase in patients and revenue in 2025. This growth is supported by a recent $8.5 million Series A funding round co-led by ManchesterStory, City Light Capital, and Threshold Ventures, bringing its total equity raised to $21.6 million. The capital is fueling the expansion of its clinical and engineering teams to meet soaring demand.

Salvo Health's strategy involves embedding its virtual care platform directly into existing GI practices, acting as an enablement layer for providers. The company has already signed enterprise agreements with three of the four largest GI practices in the country, representing a network of 801 providers who serve over 1.1 million patients annually. By integrating Lohman's unique technology, Salvo aims to solidify its position as the go-to partner for clinics looking to adopt a hybrid care model that blends in-person visits with continuous virtual support.

Connecting the Brain, Gut, and Heart

While the use of an electrocardiogram (ECG) device for gut health may seem unconventional, the partnership hinges on the growing scientific understanding of the brain-gut axis. The HomECG+ device is used to measure Heart Rate Variability (HRV), a key indicator of the autonomic nervous system's (ANS) activity. HRV provides a non-invasive way to quantify the balance between the body's stress response (the sympathetic nervous system, or "fight or flight") and its relaxation response (the parasympathetic nervous system, or "rest and digest").

Recent medical research supports this approach. A systematic review and meta-analysis of multiple studies found significant differences in HRV metrics between patients with Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) when compared to healthy individuals. This data suggests that dysregulation of the autonomic nervous system plays a role in the pathology of these chronic conditions.

Salvo Health leverages these HRV readings as a tangible biomarker for its interdisciplinary care teams—which include dietitians, nurses, and behavioral health specialists—to monitor a patient's progress. "Lohman devices enable us to offer patients an easy, wireless-connected-out-of-the-box way to see progress in managing stress that can otherwise worsen GI and cardiometabolic conditions," said Jeff Glueck, Co-Founder and CEO of Salvo Health. He added that the data helps clinicians guide patients from "'fight or flight' to 'rest and digest' mode with their parasympathetic nervous system."

This holistic method appears to be yielding results. According to Salvo Health, early data shows 80% of its patients report feeling better within six weeks, and the platform has driven a 79% reduction in GI-related emergency room visits.

Removing Barriers to Remote Care

The partnership's success also depends heavily on patient adoption, an area where Lohman's technology offers a distinct advantage. The HomECG+ is designed for simplicity, featuring patented cellular connectivity that transmits data directly to healthcare providers without requiring a patient to have a smartphone or a home Wi-Fi connection. This design choice removes significant technological barriers that often hinder remote patient monitoring programs, especially among older or less tech-savvy populations.

This feature sets it apart from many other FDA-cleared home ECG monitors, such as AliveCor's popular KardiaMobile, which relies on a smartphone to record and transmit data. By providing a device that works seamlessly out of the box, the companies aim to maximize patient engagement and ensure a consistent flow of clinical data.

"HomECG+ is the only patient-driven ECG solution that delivers clinical-grade accuracy without technology barriers," Dvorak emphasized. "This seamless integration empowers Salvo's interdisciplinary teams to provide proactive, whole patient cardiometabolic monitoring that dramatically improves outcomes, reduces hospitalizations, and sets a new benchmark for virtual chronic care platforms."

The expanded program, set to roll out throughout 2026, will bring this simplified, data-driven approach to thousands of new patients. By combining Salvo's comprehensive virtual support with Lohman's accessible technology, the partnership represents a concerted effort to make chronic disease management more proactive, personalized, and effective for patients both inside and outside the clinic walls.